1. 荷叶提取物lotus leaf extract

荷叶提取物荷叶碱

品名:荷叶提取物 
拉丁名:Folium Nelumbinis
有效成分:荷叶碱 1% 2% 5% 10% 50%,98%
检测方式:HPLC
提取溶剂:乙醇/水
CAS号:475-83-2
分子式:C19H21NO2
分子量:313.39082

荷叶碱是荷叶中的一种阿朴啡型生物碱，为荷叶中的主要降脂活性成分；以晒干粉碎的荷叶为原料，采用纤维素酶预处理、稀盐酸浸提、超声波辅助提取、氯仿萃取一系列方法提取而成。其中江西石城产区的荷叶含荷叶碱 。
中医学认为，荷叶性味苦涩，平，归肝、脾、胃、心经。有清暑利湿、升发清阳、凉血止血等功效。荷叶中的生物碱有降血脂作用、抗自由基、抑制高胆固醇血症和动脉硬化等药疗、食疗功效，而且还具有抗有丝分裂的作用，有较强的抑菌效果。

【英文名称】Nuciferin
【别名】(R)-1,2-Dimethoxyaporphine
【拉丁名称】folium nelumbinis
【分子式】C19H21NO2
【分子量】 295.376
【CAS号】475-83-2
【性状】高纯度的荷叶碱为米黄色至类白色结晶性粉末，纯度越高，色泽越浅。

功能一：
荷叶碱具有 的减肥功效

功能二：
荷叶碱拥有卓越的降脂保健作用

产品详询:13657416805

 

参考文献：

 

  1. 1.

    Zhang X, Xu R, Zhang C, Xu Y, Han M, Huang B, et al. Trifluoperazine, a novel autophagy inhibitor, increases radiosensitivity in glioblastoma by impairing homologous recombination. J Exp Clin Cancer Res. 2017;36(1):118.

  2. 2.

    Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, Quinn JA, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253–9.

  3. 3.

    Kim BM, Hong Y, Lee S, Liu P, Lim JH, Lee YH, et al. Therapeutic implications for overcoming radiation resistance in cancer therapy. Int J Mol Sci. 2015;16(11):26880–913.

  4. 4.

    Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–34. 

  5. 5.

    Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166(1):21–45.

  6. 6.

    Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017 Oct;14(10):611–29.

  7. 7.

    Phillips S, Kuperwasser C. SLUG: critical regulator of epithelial cell identity in breast development and cancer. Cell Adhes Migr. 2014;8(6):578–87.

  8. 8.

    Voutsadakis IA. Epithelial-mesenchymal transition (EMT) and regulation of EMT factors by steroid nuclear receptors in breast cancer: a review and in silico investigation. J Clin Med. 2016;5(1):E11.

  9. 9.

    Alves CC, Carneiro F, Hoefler H, Becker KF. Role of the epithelial-mesenchymal trasition regulator Slug in primary human cancers. Front Biosci (Landmark Ed). 2009;14:3035–50.

  10. 10.

    Wegner M. From head to toes: the multiple facets of sox proteins. Nucleic Acids Res. 1999;27(6):1409–20.

  11. 11.

    Mansouri S, Nejad R, Karabork M, Ekinci C, Solaroglu I, Aldape KD, et al. Sox2: regulation of expression and contribution to brain tumors. CNS Oncol. 2016;5(3):159–73.

  12. 12.

    Song WS, Yang YP, Huang CS, Lu KH, Liu WH, Wu WW, et al. Sox2, stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79(10):538–45.

  13. 13.

    Garros-Regulez L, Garcia I, Carrasco-Garcia E, Lantero A, Aldaz P, Moreno-Cugnon L, et al. Targeting SOX2 as a therapeutic strategy in glioblastoma. Front Oncol. 2016;6:222.

  14. 14.

    Chin YW, Yoon KD, Kim J. Cytotoxic anticancer candidates from terrestrial plants. Anti Cancer Agents Med Chem. 2009;9(8):913–42.

  15. 15.

    Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41:D1124–9.

  16. 16.

    Nguyen KH, Ta TN, Pham TH, Nguyen QT, Pham HD, Mishra S, et al. Nuciferine stimulates insulin secretion from beta cells-an in vitro comparison with glibenclamide. J Ethnopharmacol. 2012;142(2):488–95. 

  17. 17.

    Ho HH, Hsu LS, Chan KC, Chen HM, Wu CH, Wang CJ. Extract from the leaf of nucifera reduced the development of atherosclerosis via inhibition of vascular smooth muscle cell proliferation and migration. Food Chem Toxicol. 2010;48(1):159–68.

  18. 18.

    Kashiwada Y, Aoshima A, Ikeshiro Y, Chen YP, Furukawa H, Itoigawa M, et al. Anti-HIV benzylisoquinoline alkaloids and flavonoids from the leaves of Nelumbo nucifera, and structure-activity correlations with related alkaloids. Bioorg Med Chem. 2005;13(2):443–8.

  19. 19.

    Nakamura S, Nakashima S, Tanabe G, Oda Y, Yokota N, Fujimoto K, et al. Alkaloid constituents from flower buds and leaves of sacred lotus (Nelumbo nucifera, Nymphaeaceae) with melanogenesis inhibitory activity in B16 melanoma cells. Bioorg Med Chem. 2013;21(3):779–87.

  20. 20.

    Liu W, Yi DD, Guo JL, Xiang ZX, Deng LF, He L. Nuciferine, extracted from Nelumbo nucifera Gaertn, inhibits tumor-promoting effect of nicotine involving Wnt/β-catenin signaling in non-small cell lung cancer. J Ethnopharmacol. 2015;165:83–93.

  21. 21.

    Guo F, Yang X, Li X, Feng R, Guan C, Wang Y, et al. Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters. PLoS One. 2013;8(5):e63770.

  22. 22.

    Qi Q, Li R, Li HY, Cao YB, Bai M, Fan XJ, et al. Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach. Acta Pharmacol Sin. 2016;37(7):963–72.

  23. 23.

    Xu Y, Bao S, Tian W, Wen C, Hu L, Lin C. Tissue distribution model and pharmacokinetics of nuciferine based on UPLC-MS/MS and BP-ANN. Int J Clin Exp Med. 2015;8(10):17612–22.

  24. 24.

    Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316–23.

  25. 25.

    Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7.

  26. 26.

    Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther. 2004;3(3):305–13.

  27. 27.

    Fletcher L, Cheng Y, Muschel RJ. Abolishment of the Tyr-15 inhibitory phosphorylation site on cdc2 reduces the radiation-induced G(2) delay, revealing a potential checkpoint in early mitosis. Cancer Res. 2002;62(1):241–50.

  28. 28.

    Junyan P, Shujuan Y, Shulin G, Yan C, Xia X. The antitumor effect of DYC-279 on human hepatocellular carcinoma HepG2 cells. Pharmacology. 2016;97(3–4):177–83.

  29. 29.

    Stark GR, Taylor WR. Control of the G2/M transition. Mol Biotechnol. 2006;32(3):227–48.

  30. 30.

    Glotzer M, Murray AW, Kirschner MW. Cyclin is degraded by the ubiquitin pathway. Nature. 1991;349(6305):132–8.

  31. 31.

    Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol. 1997;9(6):788–99.

  32. 32.

    Parry DH, O'Farrell PH. The schedule of destruction of three mitotic cyclins can dictate the timing of events during exit from mitosis. Curr Biol. 2001;11(9):671–83.

  33. 33.

    Vorlaufer E, Peters JM. Regulation of the cyclin B degradation system by an inhibitor of mitotic proteolysis. Mol Biol Cell. 1998;9(7):1817–31.

  34. 34.

    Lin H, Liu XY, Subramanian B, Nakeff A, Valeriote F, Chen BD. Mitotic arrest induced by XK469, a novel antitumor agent, is correlated with the inhibition of cyclin B1 ubiquitination. Int J Cancer. 2002;97(1):121–8. 

  35. 35.

    Lee YM, Lim DY, Choi HJ, Jung JI, Chung WY, Park JH. Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin. J Med Food. 2009;12(1):8–14.

  36. 36.

    Chien CC, Wu MS, Shen SC, Ko CH, Chen CH, Yang LL, et al. Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine. PLoS One. 2014;9(6):e99729. 

  37. 37.

    Yang L, Liang H, Wang Y, Gao S, Yin K, Liu Z, et al. MiRNA-203 suppresses tumor cell proliferation, migration and invasion by targeting Slug in gastric cancer. Protein Cell. 2016;7(5):383–7. 

  38. 38.

    Vitali R, Mancini C, Cesi V, Tanno B, Mancuso M, Bossi G, et al. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models. Clin Cancer Res. 2008;14(14):4622–30.

  39. 39.

    Zhao X, Sun B, Sun D, Liu T, Che N, Gu Q, et al. Slug promotes hepatocellular cancer cell progression by increasing SOX2 and NANOG expression. Oncol Rep. 2015;33(1):149–56. 

  40. 40.

    Yang CY, Chen YD, Guo W, Gao Y, Song CQ, Zhang Q, et al. Bismuth ferrite-based nanoplatform design: an ablation mechanism study of solid tumor and NIR-triggered photothermal/photodynamic combination cancer therapy. Adv Funct Mater. 2018;28:1706827. 

  41. 41.

    Ke D, Yang R, Jing L. Combined diagnosis of breast cancer in the early stage by MRI and detection of gene expression. Exp Ther Med. 2018;16(2):467–72.

  42. 42.

    Yang HW, Menon LG, Black PM, Carroll RS, Johnson MD. SNAI2/Slug promotes growth and invasion in human gliomas. BMC Cancer. 2010;10:301.

  43. 43.

    Carpenter RL, Paw I, Dewhirst MW, Lo HW. Akt phosphorylates and activates HSF-1 independent of heat shock, leading to Slug overexpression and epithelial-mesenchymal transition (EMT) of HER2-overexpressing breast cancer cells. Oncogene. 2015;34(5):546–57.

  44. 44.

    Yao C, Su L, Shan J, Zhu C, Liu L, Liu C, et al. IGF/STAT3/NANOG/Slug signaling axis simultaneously controls epithelial-mesenchymal transition and stemness maintenance in colorectal cancer. Stem Cells. 2016;34(4):820–31.

  45. 45.

    Chen YD, Zhang Y, Dong TX, Xu YT, Zhang W, An TT, et al. Hyperthermia with different temperatures inhibits proliferation and promotes apoptosis through the EGFR/STAT3 pathway in C6 rat glioma cells. Mol Med Rep. 2017;16(6):9401–8. 

  46. 46.

    Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. 

  47. 47.

    Safa AR, Saadatzadeh MR, Cohen-Gadol AA, Pollok KE, Bijangi-Vishehsaraei K. Emerging targets for glioblastoma stem cell therapy. J Biomed Res. 2016;30(1):19–31.

  48. 48.

    van Schaijik B, Davis PF, Wickremesekera AC, Tan ST, Itinteang T. Subcellular localisation of the stem cell markers OCT4, SOX2, NANOG, KLF4 and c-MYC in cancer: a review. J Clin Pathol. 2018;71(1):88–91.

  49. 49.

    Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.

  50. 50.

    Azuaje F, Tiemann K, Niclou SP. Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma. Cell Commun Signal. 2015;13:23.

  51. 51.

    Liu Y, Wu X, Mi Y, Zhang B, Gu S, Liu G, et al. PLGA nanoparticles for the oral delivery of nuciferine: preparation, physicochemical characterization and in vitro/in vivo studies. Drug Deliv. 2017;24(1):443–51.


 

回到顶部
桌面版